Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
491 participants
INTERVENTIONAL
1998-11-30
2004-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis: Daily intake of selenium supplementation in the form of selenium-enriched yeast tablets will reduce the risk of cancer in healthy individuals.
Objective: The objective of this pilot study was to assess the viability of a full scale randomised trial.
AMENDMENT TO STUDY OBJECTIVE: Mortality analysis during intervention and follow-up as specified in the sections concerning study design and outcome measures.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predicting Dietary Selenium Needs to Achieve Target Blood Selenium Levels
NCT00803699
Selenium Status Measured in Blood After a Higher Intake of Fish and Shellfish - a Randomized Dietary Intervention Study
NCT01224249
Optimization of Selenoprotein P in Chinese Subjects
NCT00428649
Effect of Selenium Intervention on Inflammation in Older Adults
NCT01289925
Selenium and Immune Function
NCT00279812
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d
SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d
SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d
SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
Yeast tablet
SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No active liver- or kidney disease (Serum ALAT (alanine aminotransferase), alkalic phosphatase, bilirubin, creatinin or urea within 2 S.D of laboratory reference range)
* No previous cancer diagnosis
* No known HIV-infection
* Participant must understand oral and written information
* Participant must not use selenium supplementation of above 50 mcg/d
* Participant must give written consent prior to inclusion
60 Years
74 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Cancer Society
OTHER
University of Southern Denmark
OTHER
K. A. Rohde's and wife's Foundation
OTHER
The County of Funen, Denmark
OTHER_GOV
Cypress Systems, USA
UNKNOWN
The Dagmar Marshall Foundation
OTHER
The N. O. Andersen Foundation
UNKNOWN
The Danish Directory of Food and Agriculture
UNKNOWN
The Foundation of Clinical Experimental Cancer Research, Odense
UNKNOWN
The Foundation of Lily Benthine Lund
UNKNOWN
The Memory Foundation of Merchant Brogaard
UNKNOWN
Pharma Nord
INDUSTRY
Odense University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Søren Cold
M.D. PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Selenium Centre, Odense University Hospital
Odense C, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cold F, Winther KH, Pastor-Barriuso R, Rayman MP, Guallar E, Nybo M, Griffin BA, Stranges S, Cold S. Randomised controlled trial of the effect of long-term selenium supplementation on plasma cholesterol in an elderly Danish population. Br J Nutr. 2015 Dec 14;114(11):1807-18. doi: 10.1017/S0007114515003499. Epub 2015 Sep 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OUH-DK-PILOT-PRECISE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.